Further studies are essential for the development of GDF11‐ and other metabotrophins‐based systemic therapies for obesity and related cardio‐ and neurometabolic diseases, including Alzheimer's disease.1, 3. This evidence concerns the gene GDF11 and early-onset autosomal dominant Alzheimer disease.